AJMB

Bacteriostatic Potency of Fe2O3 Against Enterococcus faecalis in Synergy with Antibiotics by DDST Method

PDF - Export to EndNote - PubMed Central XML format - PubMed Central XML format - PubMed Central XML format
PMID: 31057720 (PubMed) - PMCID: PMC6490414 - View online: PubReader
Volume 11, Issue 2, April-June , Page 176 to 179
Sunday, December 31, 2017 :Received , Saturday, March 10, 2018 :Accepted


  • - Department of Microbiology, Shahid Beheshti University, Tehran, Iran
  • Corresponding author Department of Biology, Tehran North Branch, Islamic Azad University, Tehran, Iran, Tel: +98 21 22946018, Fax: +98 21 77009848, E-mail: d.zaeifi@ut.ac.ir
    - Department of Biology, Tehran North Branch, Islamic Azad University, Tehran, Iran

Abstract:

Background: In this study, bacteriostatic potency of the Iron oxide nanoparticles against Enterococcus faecalis (E. faecalis) (a clinical sample and the ATCC11700 strain) was investigated.
Methods: Nanoparticles’ bacteriostatic concentration was determined and used to appraise the characteristics of the Iron Oxide (Fe2O3) against the isolates. Antimicrobial examinations with 108cfu.ml-1 were performed at the baseline. Due to evaluation level of potency, after performing Minimum Inhibitory Concentration (MIC), the assessment of death kinetic and susceptibility constant of nanoparticles was done by suspension at two MICs in 0 to 360 min treatment time.
Results: Fe2O3 nanoparticles in size range of 10-50 nm demonstrated the most effective susceptibility reaction against E. faecalis and ATCC11700 strain in Z=78.125 ml/μg-1 and 39.0625 ml/μg-1, respectively. The kinetic reaction of E. faecalis against Fe2O3 suspension was supposed to be decreased through the elapse of treatment time, whereas increased concentration was along with bacteria growth after a certain time. So, the efficient concentration of nanoparticles was applied with semi-sensitive and antibiotic resistant for both strains. However, synergism of Fe2O3 nanoparticles with Ceftazidime and Clindamycin revealed a higher susceptibility compared with Fe2O3 nanoparticles alone against E. faecalis.
Conclusion: The experimental results reveal that Fe2O3 has a strong antimicrobial effect at a certain concentration over the time so could potentially be used for bacterial inhibition and this feature will be strengthened in combination with antibiotics.


 

 

Introduction :

Enterococci are one of the most frequent causes of nosocomial infections in the intensive care unit; they appear in this sector along with clumsily use of cephalosporins and other antibiotics to which enterococci are resistant. These bacteria are contagious and usually cause infection in the urinary tract, wound, bile duct, and blood at the hospital; also, they can cause meningitis in children and endocarditis in adults 1,2. 
Enterococcus faecalis (E. faecalis) is one of the most common species of enterococcus which causes 85 to 90% of enterococcal infections. Gram-positive bacteria were previously classified as Group D Streptococcus, due to specific antigen which is teichoic acid. Most of these bacteria are non-hemolytic and sometimes are alpha-hemolytic which can be found in natural intestinal flora 1-4.
These bacteria are resistant to many antibiotics like Meropenem, Gentamicin, Ceftriaxone, Ceftazidime, Cefixime, Trimethoprim/Sulfamethoxazole, Erythromycin, and Clindamycin with above 60% resistance frequency rate and sensitivity to Vancomycin, Teicoplanin, and Nitrofurantion based on report 3-9.
Iron oxide due to its biocompatibility and magnetic feature has been widely used in biomedical research 10,11. Nanoparticles (NP) of Iron oxide with certain sizes (almost less than 100 nm), are applied for targeted drug delivery as carriers for many types of cancer 12,13. Moreover, nanoparticles are used for drug delivery system which were extended for directing nanoparticles by using an external magnetic field in particular places due to accurate treatment 14. Therefore, it is assumed that Reactive Oxygen Species (ROS) produced by nanoparticles have a bacteriostatic potency without damaging eukaryotic cells 15,16. 
The aim of this study was to find a way to prevent drug resistance by using lower doses of antibiotics to treat the bacterial infections.

 

Materials and Methods :

The reference strain, E. faecalis (ATCC 11700), was used as the control strain in all steps for comparison purposes.
Preparation of culture medium: In total, 20 culture-positive specimens of E. faecalis were collected from patients at Tehran University of Medical Sciences and cultured on Bile Esculin Agar (Merck, Germany) 17,18.
Kirby-Bauer Susceptibility Test: In order to test the resistance of E. faecalis, clinical-positive specimens of these bacteria were cultured on Mueller Hinton agar medium (Merck, Germany). Disk diffusion was performed using Kirby-Bauer method (Clindamycin 2 μg, Oxacillin 1 μg, Erythromycin 15 μg, Cefotaxime 30 μg, Ceftazidime 30 μg, Tetracycline 30 μg, Chloramphenicol 30 μg, Vancomycin 30 μg disks, Mast Group Ltd Company, UK). Incubation was performed for 24 hr at 37oC with 5% CO2 (Semi-aerobic conditions). The isolate with higher resistance was selected for further study.
Preparation of nanoparticle (NP) suspension: Fe2O3 nanoparticles (Purity over 99.7%) with 10-50 nm range size were purchased from US NANO. Nanoparticles stock solution was prepared by suspending one gram of nanoparticles into 100 ml sterile medium and dispersion was done by Electro sonic system (Bandelier Sonorex RK 31H) for 35 min. The microbial tests and preparation of nanoparticle suspensions were performed simultaneously in order to reduce probable errors.
Microbial suspension preparation: At first, bacterial cells were collected from BEA culture medium and were mixed in 10 ml Phosphate-Buffered Saline (PBS) in order to prepare samples with 0.5 McFarland Turbidity [1-1.5×108 Colony-Forming Unit (CFU)] and the accuracy was measured by spectrophotometer (UNICO-2100; USA) at 620 nm wavelength range and absorbance was set at the range from 0.08 to 0.1 nm.
MIC test and bacteriostatic potency: The Clinical and Laboratory Standards Institute (CLSI) recommendations were used for Minimal Inhibitory Concentration (MIC) calculation of the sample in contact with the NP suspension. Gradient concentrations of Fe2O3NPs suspension, both NPs with bacteria, were prepared according to a conducted study by Khavarani et al 18,19.
Nanoparticles impregnated discs preparation: Sterile blank discs (Crude) were placed in a plate, then nanoparticle suspension with desired concentration was poured into the plate, where the discs were not immersed, then incubated about 24 hr at room temperature until the suspension was completely absorbed by blank discs 20.
DDST susceptibility test: The antibiotics to which the isolate showed resistance or semi-susceptibility were selected and assessed for DDST in Mueller Hinton agar medium with 20 mm center to be centered in the plate. Incubation was performed for 18 hr at 37°C and the inhibition zone from the edge of each disc was recorded 19.

 

Results :

Kirby-Bauer Susceptibility Test: The isolated bacteria were resistant to Oxacillin and Ceftazidime, and semi-sensitive to Tetracycline and Chloramphenicol acid antibiotics (Table 1).
Preparation of the nanoparticle suspensions: The X-ray powder diffraction (XRD) diagram of the commercial Fe2O3 powder in figure 1A demonstrates the proper purity due to lack of any impurity diffraction pattern. Figure 1B presents the corresponding morphology and particle size distributions of prepared Fe2O3 powders by TEM microscopy.
MIC test and bacteriostatic potency: According to the results, the antimicrobial activity of Iron oxide nanoparticles suspensions against E. faecalis, the MIC for the isolated bacteria and ATCC11700 strain against Iron oxide NPs were Z=78.125 ml/μg-1 and 39.0625 ml/μg-1, respectively. The sensitivity coefficient for E. faecalis against the nanoparticle suspension was calculated for each sampling period. The mean of bacterial coefficient sensitivity to the nanoparticles is shown in figure 2.
DDST susceptibility tes: The results in table 1 show higher antibacterial activity for Clindamycin, Oxacillin, and Ceftazidime due to visibility of the zone; however, it seems Chloramphenicol in synergy with the applied Fe2O3 did not increase the inhibitory zone significantly.

 

Discussion :

XRD and TEM images illustrate the appropriate crystal structure of synthesized Iron oxide NPs and have almost regular spherical shape in the size range of nano. Some bacteria have the potency in reducing metal oxide by mechanisms 15,16, therefore reducing the size of Iron NPs would not be a good idea for increasing toxicity of metal oxide 21; but nanoparticles with higher number of reactive groups on the surface like active sites for the formation of ROS which lead to oxidative stress could be good candidates 15,22. 
Many studies reveal that in aquatic system, the antimicrobial activity of metal oxide compounds was mainly caused by soluble ions, and has effect on reduced cellular function due to aggregation of NPs in aqueous medium 23. But at efficient concentration, NPs at dilution condition can be more toxic for cells than the metal ionic form which is described as a nano-trojan horse type of mechanism 22.
According to figure 2, NPs inhibitory properties against E. faecalis were enhanced by increasing nanoparticles concentration. But higher concentration of nanoparticles leads to slight growth; so, Iron oxide nanoparticles had no bactericidal effect on tested strains.
Previous studies represent that, if the environmental pH is lower than the pH of NPs, the surface of NPs could be positively charged and vice-versa 24. Theoretically, the pH values of Fe2O3 NPs have been calculated to be 5-7. Due to lack of significant difference between both pH values (pH of microorganism is about 2-4), this opinion could not be justifiable. 
The results express that Chloramphenicol in synergy with NPs could not increase inhibitory effect significantly (Table 1). According to the given explanations, surface charge of bacteria is reduced due to repulsion 25. Therefore, greater concentration of NPs due to this electrostatic repulsion force cannot be a suitable option to overcome this inhibitory force 24.

 

Conclusion :

Based on our findings, it can be inferred that Iron oxide nanoparticles suspension in different concentrations has growth inhibitory effects against bacteria that cause nosocomial infections, but at higher concentrations than the MIC, presumably it can make adaption to Fe2+ ions which could be used as a source of energy in metabolic pathway.
The use of bacteriostatic potency of these NPs against bacteria suspensions with certain concentration in combination with antibiotics can be a good option for inhibition of the bacterial infections in medical domains.

 

Conflict of Interest :

Authors declare no conflict of interest.

 



<p>Figure 1. A) XRD of Fe<sub>2</sub>O<sub>3 </sub>nanoparticles, B) TEM of the Fe<sub>2</sub>O<sub>3 </sub>nanoparticles.</p>

Figure 1. A) XRD of Fe2O3 nanoparticles, B) TEM of the Fe2O3 nanoparticles.


<p>Figure 2. <em>E. faecalis</em> population coefficient sensitivity due to the time of investigation. A) ATCC11700 (MIC after 180 <em>min</em>)-B) Clinical sample (MIC after 120 <em>min</em>).</p>

Figure 2. E. faecalis population coefficient sensitivity due to the time of investigation. A) ATCC11700 (MIC after 180 min)-B) Clinical sample (MIC after 120 min).


<p>Table 1. Sensitivity of the <em>E. faecalis </em>to the applied antibiotics and in synergy with Fe<sub>2</sub>O<sub>3</sub> nanoparticles</p> <p>* (NA)-did not test.</p>

Table 1. Sensitivity of the E. faecalis to the applied antibiotics and in synergy with Fe2O3 nanoparticles

* (NA)-did not test.


References :
  1. Hasani A, Sharifi Y, Ghotaslou R, Naghili B, Hasani A, Aghazadeh M, et al. Molecular screening of virulence genes in high-level gentamicin-resistant Enterococcus faecalis and Enterococcus faecium isolated from clinical specimens in Northwest Iran. Indian J Med Microbiol 2012;30(2):175-181.   [PubMed]
  2. Sadeghifard N, Kazemian H, Mohebi R, Sekawi Z, Khosravi A, Valizadeh N, et al. Epidemiological alteration in pathogens found in ground meat in Iran: unexpected predominance of vancomycin-resistant Enterococcus faecalis. GMS Hyg Infect Control 2015;10:Doc12.   [PubMed]
  3. Feizabadi MM, Maleknejad P, Asgharzadeh A, Asadi S, Shokrzadeh L, Sayadi S. Prevalence of aminoglycoside-modifying enzymes genes among isolates of Enterococcus faecalis and Enterococcus faecium in Iran. Microb Drug Resist 2006;12(4):265-268.   [PubMed]
  4. Mohammadi F, Ghafourian S, Mohebi R, Taherikalani M, Pakzad I, Valadbeigi H, et al., Enterococcus faecalis as multidrug resistance strains in clinical isolates in Imam Reza Hospital in Kermanshah, Iran. Br J Biomed Sci 2015;72(4):182-184.   [PubMed]
  5. Gajan EB, Abashov R, Aghazadeh M, Eslami H, Oskouei SG, Mohammadnejad D. Vancomycin-resistant Enterococcus faecalis from a wastewater treatment plant in Tabriz, Iran. Pak J Biol Sci 2008;11(20):2443-2446.   [PubMed]
  6. Sharifi Y, Hasani A, Ghotaslou R, Varshochi M, Hasani A, Aghazadeh M, et al. Survey of virulence determinants among vancomycin resistant enterococcus faecalis and enterococcus faecium isolated from clinical specimens of hospitalized patients of north west of Iran. Open Microbiol J 2012;6:34-39.   [PubMed]
  7. Khani M, Fatollahzade M, Pajavand H, Bakhtiari S, Abiri R. Increasing prevalence of aminoglycoside-resistant enterococcus faecalis isolates due to the aac(6')-aph(2") gene: a therapeutic problem in Kermanshah, Iran. Jundishapur J Microbiol 2016;9(3):e28923.   [PubMed]
  8. Heidari H, Hasanpour S, Ebrahim-Saraie HS, Mota-medifar M. Ebrahim-Saraie. High incidence of virulence factors among clinical enterococcus faecalis isolates in southwestern Iran. Infect Chemother 2017;49(1):51-56.   [PubMed]
  9. Feizabadi MM, Asadi S, Zohari M, Gharavi S, Etemadi G. Genetic characterization of high-level gentamicin-resistant strains of Enterococcus faecalis in Iran. Can J Microbiol 2004;50(10):869-872.   [PubMed]
  10. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005;26(18):3995-4021.   [PubMed]
  11. Wu W, Jiang CZ, Roy VA. Designed synthesis and surface engineering strategies of magnetic iron oxide nanoparticles for biomedical applications. Nanoscale 2016;8(47):19421-19474.   [PubMed]
  12. Kohler N, Sun C, Wang J, Zhang M. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 2005;21(19):8858-8864.   [PubMed]
  13. Chertok, B, Moffat BA, David AE, Yu F, Bergemann C, Ross BD, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008;29(4):487-496.   [PubMed]
  14. Pareta RA, Taylor E, Webster TJ. Increased osteoblast density in the presence of novel calcium phosphate coated magnetic nanoparticles. Nanotechnology 2008;19(26):265101.   [PubMed]
  15. Ortiz de Orué Lucana D, Wedderhoff I, Groves MR. ROS-mediated signalling in bacteria: zinc-containing cys-x-x-cys redox centres and iron-based oxidative stress. J Signal Transduct 2012;2012:605905.   [PubMed]
  16. Cornelis, P, Wei Q, Andrews SC, Vinckx T. Iron homeostasis and management of oxidative stress response in bacteria. Metallomics 2011;3(6):540-549.   [PubMed]
  17. Barry AL, Craig WA, Nadler H, Reller LB, Sanders CC, Swenson JM. Methods for determining bactericidal activity of antimicrobial agents: approved guideline. USA: National Committee for Clinical Laboratory Standards; 1999. Vol. 19, No 18.
  18. Food, U. and D. Administration, Division of Anti-infective and Ophthalmology Drug Products (HFD-520)-Microbiological data for antibacterial drug products-development, analysis, and presentation. FDA. 2005.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021821orig1s000micror.pdf.
  19. Fathi Azar Khavarani M, Najafi M, Shakibapour Z, Zaeifi D. kinetics activity of yersinia intermedia against ZnO nanoparticles either synergism antibiotics by double-disc synergy test method. Iran J Biotechnol 2016;14(1):39-44.   [PubMed]
  20. Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal 2016;6(2):71-79.   [PubMed]
  21. Asakawa S, Bünemann E, Frossard E. Microbially Mediated Processes. In: Huang PM, Li Y, Sumner ME, editors. Handbook of Soil Sciences. Boca Raton, Florida: CRC Press; 2011. p. 1-52.
  22. Limbach LK, Wick P, Manser P, Grass RN, Bruinink A, Stark WJ. Exposure of engineered nanoparticles to human lung epithelial cells:  influence of chemical composition and catalytic activity on oxidative stress. Environ Sci Technol 2007;41(11):4158-4163.
  23. Wu B, Huang R, Sahu M, Feng X, Biswas P, Tang YJ. Bacterial responses to Cu-doped TiO2 nanoparticles. Sci Total Environ 2010;408(7):1755-1758.   [PubMed]
  24. Ruparelia JP, Chatterjee AK, Duttagupta SP, Mukherji S. Strain specificity in antimicrobial activity of silver and copper nanoparticles. Acta Biomater 2008;4(3):707-716.   [PubMed]
  25. Yoon KY, Hoon Byeon J, Park JH, Hwang J. Susceptibility constants of Escherichia coli and Bacillus subtilis to silver and copper nanoparticles. Sci Total Environ 2007;373(2-3):572-575.   [PubMed]